The G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2020-30 by The Business Research Company describes and explains the global G-CSF (granulocyte colony stimulating factors) market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The G-CSF (Granulocyte Colony Stimulating Factors) Global Market Opportunities And Strategies Report covers G-CSF (granulocyte colony stimulating factors) market drivers, G-CSF (granulocyte colony stimulating factors) market trends, G-CSF (granulocyte colony stimulating factors) market segments, G-CSF (granulocyte colony stimulating factors) market growth rate, G-CSF (granulocyte colony stimulating factors) market major players, and G-CSF (granulocyte colony stimulating factors) market size.
View Complete Report:
https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market
The G-CSF (granulocyte colony stimulating factors) market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.
G-CSF (Granulocyte Colony Stimulating
Factors) Global Market Opportunities And Strategies Report is the most
comprehensive report available on this market and will help gain a truly global
perspective as it covers 60 geographies. The chapter on the impact of COVID-19
gives valuable insights on supply chain disruptions, logistical challenges, and
other economic implications of the virus on the market. The chapter also covers
markets which have been positively affected by the pandemic.
Request For The Sample Now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3930&type=smp
Robust Research & Development -
The G-CSF market is witnessing robust
research and development activities. These research and development activities
have led to increasing success rates in clinical trials. Research and
development is being carried out by market leaders in the Granolocyte Colony
Stimulating Factors market as they continuously strive to make breakthroughs in
the market in the form of new and effective drugs. For instance, as of October
2020, Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel
and targeted oncology therapies is anticipating FDA approval for a Biologics
License Application (BLA) for ROLONTIS, a novel, long-acting granulocyte
colony-stimulating factor (G-CSF), an indication for the treatment of
neutropenia in patients receiving myelosuppressive anti-cancer drugs. Also,
many drugs are in pipeline under development by some of the major companies
such as Amgen, Biocon.
Large Number Of Strategic Partnerships In The Global Granulocyte Colony Stimulating Factors Market -
Companies in the Granolocyte Colony
Stimulating Factors market are increasing their product innovation through
strategic collaborations. To sustain in the increasingly competitive market,
companies are developing innovative products as well as sharing skills and
expertise with other companies. While companies have long collaborated with
each other as well as with academic and research institutions in this market by
way of partnerships, in or out-licensing deals, this trend has been increasing
over recent years. For instance, in September 2020, Humanigen, Inc., a clinical
stage biopharmaceutical company collaborated with Lonza and Catalent to expand
manufacturing of COVID-19 therapeutic candidate Lenzilumab. Lenzilumab is the
patented Humaneered® anti-human granulocyte macrophage-colony stimulating
factor (GM-CSF) monoclonal antibody with the potential to prevent and treat cytokine
storm, which is believed to cause the acute respiratory distress syndrome in
severe COVID-19 cases.
The G-CSF market is segmented:
By Type -
a) Pegfilgrastim
b) Filgrastim
c) Lenograstim
d) Others
By Application-
a) Oncology
b) Blood Disorders
c) Chronic and Autoimmune Disorders
d) Others
About The Business Research Company:
The Business
Research Company is a market intelligence firm that excels in company, market,
and consumer research. Located globally it has specialist consultants in a wide
range of industries including manufacturing, healthcare, financial services,
chemicals, and technology. It has offices in the UK, the US and India and
a network of trained researchers in 20+ countries globally.
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Comments
Post a Comment